deltatrials
Unknown PHASE2 INTERVENTIONAL NCT00159094

A Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer

A Phase II Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer

Sponsor: Hematology Oncology Consultants

Conditions Metastatic Breast Cancer
Interventions Doxil and Vinorelbine
Updated 5 times since 2017 Last updated: May 30, 2008 Started: Oct 31, 2003
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Metastatic Breast Cancer, this trial is ongoing. The trial is conducted by Hematology Oncology Consultants and has accumulated 5 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotUnknown Status~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 24 months · monthly snapshotUnknown

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE2

    First recorded

Oct 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hematology Oncology Consultants
  • Ortho Biotech, Inc.
Data source: Hematology Oncology Consultants

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations